D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $31.00 target price on the stock.

Other research analysts also recently issued research reports about the stock. Ascendiant Capital Markets increased their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Friday, March 14th.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $2.20 on Monday. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $6.01. The firm has a fifty day moving average price of $2.94 and a 200-day moving average price of $2.02. The company has a market cap of $37.22 million, a price-to-earnings ratio of -1.03 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Equities research analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. AdvisorShares Investments LLC lifted its holdings in shares of NRx Pharmaceuticals by 138.5% in the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock valued at $683,000 after acquiring an additional 180,229 shares during the last quarter. Anson Funds Management LP raised its position in NRx Pharmaceuticals by 30.3% in the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after purchasing an additional 43,135 shares during the period. Millennium Management LLC purchased a new stake in NRx Pharmaceuticals in the 4th quarter worth about $61,000. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals in the 4th quarter worth about $56,000. Finally, Townsquare Capital LLC purchased a new stake in NRx Pharmaceuticals in the 3rd quarter worth about $25,000. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.